GPB Passport icon GPB Passport icon Passport
GPB donate icon GPB donate icon Donate
Sign Up For Our Newsletter

News Articles: leqembi

A large study of an experimental Alzheimer's drug made by pharmaceutical company Eli Lilly & Co. appears to slow worsening of the degenerative brain disease.

An experimental Alzheimer's drug outperforms one just approved by the FDA

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.

|
By:
  • Jon Hamilton
The Food and Drug Administration has fully approved Leqembi, the first drug shown to slow down Alzheimer's disease.

Alzheimer's drug Leqembi gets full FDA approval. Medicare coverage will likely follow

The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.

|
By:
  • Jon Hamilton
U.S. health officials approved Leqembi, a new Alzheimer's drug that modestly slows the brain disease. The FDA granted accelerated approval Friday for patients in early stages of Alzheimer's.

FDA approves Alzheimer's drug that appears to modestly slow disease

An Alzheimer's drug that removes the substance amyloid from the brain has received a conditional approval from the FDA. A large study found the drug decreased the loss of thinking and memory by 27%.

|
By:
  • Jon Hamilton